POZEN Inc was incorporated in the State of Delaware on September 25, 1996. The Company is a pharmaceutical company focused on transforming medicines that can transform lives. The Company is engaged in developing products that address unmet medical needs in the marketplace, obtaining patents for those ideas which the company believes has value in the marketplace, utilizing a small group of talented employees to develop those ideas by working with strategic outsource partners, developing a regulatory pathway with the appropriate agency, and determining how to commercialize its products. The Ccompany has developed Treximet in collaboration with GlaxoSmithKline, or GSK. Treximet is the brand name for the product combining sumatriptan 85 mg, formulated with RT Technology and naproxen sodium 500 mg in a single tablet designed for the acute treatment of migraine. The Company has also developed VIMOVO with AstraZeneca AB, or AstraZeneca. VIMOVO (formerly referred to as PN 400) is the brand name for a proprietary fixed dose combination of the PPI esomeprazole magnesium with the NSAID naproxen in a single tablet. The competition for VIMOVO comes from the oral anti-arthritic market, or more specifically the traditional non-selective NSAIDs (such as naproxen and diclofenac), traditional NSAID/gastroprotective agent combination products or combination product packages (such as Arthrotec and Prevacid NapraPAC) and the only remaining COX-2 inhibitor, Celebrex. The Companys product candidates under development are subject to extensive domestic and foreign regulation.